SCHEMBL3072148

SCHEMBL3072148

O=c1cc(O)c2cc(Cl)c(Cl)cc2o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 5/20 0.59
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 3/20 0.56
KMT2A Q03164 3/20 0.56
CA12 O43570 3/20 0.53
CA9 Q16790 3/20 0.53
CA1 P00915 1/20 0.53
PIM1 P11309 1/20 0.53
AHR P35869 1/20 0.52
CYP3A4 P08684 1/20 0.47
THRB P10828 1/20 0.47
AKR1B1 P15121 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MEN1 O00255 2/20 0.45
MAPT P10636 1/20 0.45
LMNA P02545 1/20 0.45
PPARG P37231 1/20 0.45
NCOA2 Q15596 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3075970 0.85 MCL1 (0.66) MCL1ALDH1A1KDM4EKMT2ACA12
SCHEMBL5088684 0.81 MCL1 (0.53) MCL1ALDH1A1KDM4EKMT2ACA12
SCHEMBL6365673 0.81 MCL1 (0.68) MCL1ALDH1A1KDM4EKMT2ACA12
SCHEMBL6190197 0.81 AHR (0.58) MCL1ALDH1A1KDM4EKMT2ACA12
SCHEMBL5346628 0.77 ALDH1A1 (0.68) MCL1ALDH1A1KDM4EKMT2ACA12
SCHEMBL3075754 0.77 PIM1 (0.64) MCL1ALDH1A1KDM4EKMT2ACA12
SCHEMBL2761996 0.76 ALDH1A1 (0.61) MCL1ALDH1A1KDM4EKMT2ACA12
SCHEMBL24302900 0.76 ALDH1A1 (0.51) MCL1ALDH1A1KDM4EKMT2ACA12
SCHEMBL30696157 0.76 ALDH1A1 (0.51) MCL1ALDH1A1KDM4EKMT2ACA12
Water SCHEMBL7080062 0.74 ALDH1A1 (0.59) MCL1ALDH1A1KDM4EKMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2825261-A1 POLYPEPTIDES AND THEIR USE Novabiotics Limited (GB) 2015-01-21 EP disclosed
US-20140155321-A1 Polypeptides and Their Use NOVABIOTICS LIMITED (GB) 2014-06-05 US disclosed
WO-2013136040-A1 POLYPEPTIDES AND THEIR USE NOVABIOTICS LIMITED (GB) 2013-09-19 WO disclosed
US-20100267653-A1 USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY NOVABIOTICS LIMITED (GB) 2010-10-21 US disclosed
US-3993670-A OPTICAL BRIGHTENERS BAYER AKTIENGESELLSCHAFT (DT) 1976-11-23 US disclosed
US-3971731-A OPTICAL BRIGHTENER, UV ABSORBER BAYER AKTIENGESELLSCHAFT (DT) 1976-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267653-A1 USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY DPM1, XPO5, NISCH MCL1 2181/4885ALDH1A1 1883/4885KDM4E 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.